What is the dose and frequency of Polymyxin B (Polymyxin B) and Trimethoprim (Trimethoprim) ophthalmic solution for conjunctivitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Polymyxin B-Trimethoprim Ophthalmic Solution Dosing for Conjunctivitis

For mild to moderate bacterial conjunctivitis, instill 1 drop in the affected eye(s) every 3 hours (maximum 6 doses per day) for 7 to 10 days. 1

Dosing Regimen

  • Standard dosing: 1 drop every 3 hours while awake, up to 6 times daily 1
  • Treatment duration: 7 to 10 days 1
  • Pediatric patients: Same dosing as adults for children over 2 months of age 1

Clinical Response Timeline

  • Reassess at 3-4 days: Patients should return if no improvement is noted 2, 3
  • Expected response: Look for reduced pain, decreased discharge, lessened lid edema, and reduced conjunctival injection 2
  • 48-hour benchmark: Studies show only 44% of patients treated with polymyxin B-trimethoprim achieve complete resolution by 48 hours, compared to 81% with moxifloxacin 4

Important Clinical Considerations

Efficacy limitations: While polymyxin B-trimethoprim is FDA-approved and effective, it demonstrates slower clinical response compared to fourth-generation fluoroquinolones 4. Research shows that by 48 hours, less than half of patients achieve complete symptom resolution with this combination 4.

When to consider alternatives: 2, 5

  • If no improvement after 3-4 days of therapy
  • For severe bacterial conjunctivitis with marked purulent discharge
  • When faster resolution is clinically important to reduce transmission

Spectrum coverage: Polymyxin B-trimethoprim provides broad-spectrum coverage against common conjunctival pathogens including H. influenzae and S. pneumoniae 6, 7, making it appropriate for empiric therapy in mild to moderate cases 3.

Critical Pitfalls to Avoid

  • Do not reduce dosing frequency below 3-4 times daily: Lower doses are subtherapeutic and promote resistance 2
  • Do not continue beyond recommended duration without reassessment: Prolonged use causes ocular surface toxicity 2, 3
  • Do not use as monotherapy for gonococcal or chlamydial conjunctivitis: These require systemic antibiotics 8, 5

Special Populations Requiring Different Management

Neonates with ophthalmia neonatorum: May require systemic antibiotics in addition to topical therapy depending on causative organism 3

Severe bacterial conjunctivitis: Consider fourth-generation fluoroquinolones (moxifloxacin 0.5% or gatifloxacin 0.5%) dosed 3 times daily, which provide superior gram-positive coverage and faster clinical response 2, 5

References

Guideline

Gentamicin Drops for Bacterial Conjunctivitis: Alternative Agents and Treatment Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Bacterial Conjunctivitis with Bacitracin Polymyxin B

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Bacterial Conjunctivitis with Fluoroquinolone Eye Drops

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Comparison of three topical antimicrobials for acute bacterial conjunctivitis.

The Pediatric infectious disease journal, 1988

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.